Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03510689 · ClinicalTrials.gov registry record
Genetics and Heart Health After Cancer Therapy
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 79
- Enrollment target
NCT03510689 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 79 participants.
The verdict
NCT03510689 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 79 participants
- Enrollment target
Study Summary
The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease
Interventions
- OTHER Blood Collection
- OTHER Cardiopulmonary Exercise Testing
- DIAGNOSTIC_TEST echocardiography
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2017-12-05 |
| Est. Completion | 2022-05-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03510689
The ClinicalTrials.gov registry entry for NCT03510689 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Blood Collection is the first listed.
NCT03510689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03510689 about?
NCT03510689 is a clinical study titled "Genetics and Heart Health After Cancer Therapy". The overall objective of this study is to use patient-centered in vitro and in vivo models to answer the fundamental question of whether or not pathogenic mutations in BRCA1/2 result in an increased risk of CV disease
What is the current status of trial NCT03510689?
This trial is currently completed. The enrollment target is 79 participants. The study started on 2017-12-05. Estimated completion is 2022-05-31.
What interventions are being tested in trial NCT03510689?
The interventions under investigation include: Blood Collection (OTHER), Cardiopulmonary Exercise Testing (OTHER), echocardiography (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03510689?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.